Clinical Trials Browser

Paroxysmal nonkinesigenic dyskinesia, Leukemia, Neoplasm Metastasis, Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04024761 2026-04-03

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Phase 1 Recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Phase 1 Recruiting

42 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

Phase 1 Recruiting

22 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Clinical Trials

Study of Tazemetostat in Lymphoid Malignancies

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

ThINKK-01

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Revumenib in Combination With 7+3 + Midostaurin in AML